| | Webinar: 2021 Apollo Healthcare Predictions Thursday, February 4, 2021 | 1pm ET / 10am PT With so much disruption from COVID-19, this year’s global insights will provide a unique window into the minds of those professionals perhaps most tested by 2020 and their hopes and perspectives for 2021. Register Now! |
Pfizer and BioNTech, scaling up for 2B coronavirus vaccine doses, temporarily cut deliveries in EU, Canada Thermo Fisher nets handheld COVID-19 test maker Mesa Biotech with $550M deal HHS finalizes rule that imposes term limits for career federal scientists UnitedHealthcare launches new virtual primary care offering in 11 states Healthcare roundup: Hackers using COVID-19 vaccine lures to attack businesses Biopharma roundup: AstraZeneca, Sinovac shots win Brazilian nod Gritstone adds COVID-19 to the pipeline with NIAID-supported vaccine Horizon switched up strategy for Tepezza launch, moving quickly to DTC to reach eye disease patients Featured Story | By Eric Sagonowsky Last week, Pfizer and BioNTech said they were boosting vaccine production to 2 billion doses this year. There's a catch, though: Scaling up a factory in Belgium to help meet that goal means supplies will run short temporarily. read more |
| |
|---|
|
Top Stories By Conor Hale Thermo Fisher Scientific continues to spend the massive windfall from COVID-19 testing that it’s gathered over the past year, with its second nine-digit acquisition in less than a week. read more By Robert King HHS published a final rule that would impose five-year term limits on career government scientists and reassign them. read more By Paige Minemyer UnitedHealthcare is launching a new, virtual primary care option as part of an effort to expand access to local clinicians in its employer-sponsored plans. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale Pfizer and BioNTech's vaccine deliveries will run short in several regions as the companies wrap a factory upgrade in Belgium. . Brazil OK'd AstraZeneca and Sinovac's shots. Gritstone Oncology is working on a next-generation COVID-19 vaccine hopeful. And Thermo Fisher will pay $550 million to buy handheld test maker Mesa Biotech. read more By Amirah Al Idrus Gritstone Oncology, the biotech working on cancer vaccines based on traditional infectious disease immunology, is bringing that approach back to its roots. It’s working on a vaccine against SARS-CoV-2, the virus that causes COVID-19, that could also work against other viruses in this family in the case of a future pandemic. read more By Sharon Klahr Coey,Beth Snyder Bulik When 77% of ophthalmologist offices closed during the pandemic, Horizon got creative to get the word out about its then-newly approved thyroid eye disease med Tepezza. It built a network of more than 1,000 infusion centers, moved to digital communications with doctors and quickly launched DTC advertising. read more |
